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1. INTRODUCTION 
1.1. ORAL SOLID DOSAGE FORMS – A CONVENIENT DRUG DELIVERY 
SYSTEM 
The conventional oral drug delivery has been known for decades is the most 
widely utilized route of administration among all the routes. It remains the preferred 
route of administration in the discovery and development of new drugs candidates and 
formulation. The popularity of oral route is attributed to patient acceptance, ease of 
administration,1-2 accurate dosing, cost effective manufacturing methods, and 
generally improve shelf life of the product. In fact the development of a 
pharmaceutical product for oral drug delivery, irrespective of its physical form (solid, 
semisolid, or liquid dosage form) involves varying contents of optimization of dosage 
form characteristics within the inherent constraints of gastrointestinal physiology1 
Oral solid dosage forms such as tablets and capsules has been formulated and 
developed nowadays since they are most effective routes of administration of a new 
drug. Pharmaceutical products designed for oral delivery and currently available on 
the prescription and over the counter markets are mostly the immediate release type, 
which are designed for immediate release of drug for rapid absorption. Many new 
generations of pharmaceutical products called controlled release and sustained release 
drug delivery system have been developed. Although these new systems are in fast 
progression, for many drugs and therapeutic indications, conventional oral solid 
immediate release drug delivery systems provided satisfactory clinical performance 
with an appropriate balance of efficacy and safety. 
The major drawbacks in developing a controlled release and sustained release 
drug delivery systems are outlined as given below:  
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1.1.1.Drawbacks in Controlled Release and Sustained Release Drug Delivery 
System. 
Decreased systemic availability3 when compared with immediate release 
conventional dosage forms due to incomplete release, increased first pass metabolism, 
increased instability, and insufficient residence time for complete release, site-specific 
absorption, and pH-dependantsolubility. Poorin-vitro in-vivo correlation.Possibility of 
dose dumping due to food, physiologic or formulation variables or chewing or 
grinding of oral formulations by patient and thus, increased risk of toxicity. 
Difficulty in retrieval of drug is in case of toxicity, poisoning and hypersensitivity 
reactions. Reduced potential for dosage adjustment of drugs normally administered in 
varying strengths. Higher cost of formulation. 
1.2.ORAL SOLID DOSAGE FORMSAS GENERIC PRODUCT DEVELOPMENT 
Oral solid dosage forms such as tablets or capsules can be developed into an 
immediate release or modified release generic product. A generic drug product, is also 
referred as a multisource Pharmaceutical product, is essentially identical to the brand 
name drug product in terms of active ingredient, strength, dosage form, route of 
administration, quality, safety, efficacy, performance characteristics, and therapeutic 
identification5 
The development of a single dosage oral tablet requires six key decisions and they 
are listed below      
 Reference listed drug (RLD or innovator drug) 
 Active material 
 Non-active ingredients 
 Container- closure system 
  Introduction 
Department of Pharmaceutics    3     J.K.K.Nattraja College of Pharmacy 
 Comparative dissolution procedure 
 Bioequivalence to the RLD 
1.3. IMMEDIATE RELEASE ORAL SOLID DOSAGE FORMS 
Immediate release solid oral dosage forms are formulations of tablets, capsules 
that are designed to disintegrate and release the drug in absence of any controlling 
features such as coatings or other formulation techniques6 
1.3.1. Tablets  
Compressed tablets are defined as solid-unit dosage forms made by 
compaction of the formulation containing the drug and certain fillers or excipients 
selected to aid in the processing and properties of the drug product. 
Reasons for preferring tablets as dosage forms are 
 Accurate dosage 
 Good physical and chemical stability. 
 Cost effective 
 Elegant appearance and patient compliance. 
1.3.1.1. Advantages of tablets  
 They provide an accurately measured dose and low content variability of the 
unit dose. 
 They are of low manufacturing cost. 
 They are easy to package and ship. 
 They are simple to identify.  
 Manufacturing processes and techniques provide tablets certain special release 
products such as enteric and delayed release products7 
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1.3.1.2. Disadvantages 
 Some drugs may cause local irritation effect harmful to gastrointestinal 
mucosa. 
 Some drugs resist compression into dense compacts, owing to their amorphous 
nature or flocculent, low-density character. 
 Bitter tasting drugs, drug with obnoxious odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation / entrapment prior 
to compression. 
1.3.2. Excipientsused in Formulation of Tablets 
 The excipients used in formulation of tablets are  
1.3.2.1. Diluents 
They are bulking agents added to the active ingredient in sufficient quantity to 
make a reasonably sized tablet. Examples: Lactose, Sucrose, Dextrose, Mannitol, 
Sorbitol, Starch, Microcrystalline Cellulose, Calcium phosphate (dibasic and tribasic) 
1.3.2.2. Binders 
Binders or Adhesives are the substances that promote cohesiveness. It is 
utilized for converting powder into granules through a process known as Granulation. 
Examples: Gelatin, Glucose, Methylcellulose, Water, Acacia, Polyvinyl pyrrolidone, 
Sorbitol. 
1.3.2.3. Glidants 
A glidant is a substance that improves the flow characteristics of a powder 
mixture and is added in the dry state prior to compression. The most commonly used 
glidants are colloidal silicon dioxide (Cabosil®, Cabot®) and syloid. They are used in 
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concentration less than 1%. Talc is also used and may serve the dual purpose of 
lubricant/glidant. 
1.3.2.4. Lubricants  
Lubricants are the substance which prevent adhesion of the tablet material to 
the surface of the dies and punches, reduce inter particle friction, facilitate an easy 
ejection of tablets from the die cavity and improves rate of flow of granules. 
Commonly used lubricants are Talc, Magnesiumstearate, Calcium stearate, Stearic 
acid, Hydrogenated vegetable oil and PEG. The quantity of lubricant significantly 
varies from 0.1 to 5%. 
1.3.2.5. Disintegrants 
Disintegrants are the substances added to a tablet to facilitate its break up or 
disintegration after administration. Examples: Starch1500(5to15%w/w), 
AvicelpH101,102 (Microcrystalline cellulose (5 to15 %w/w), Sodium starch 
glycolate, Polyvinyl pyrrolidone (PVP) and cross linked Polyvinyl pyrrolidone, 
Sodium Carboxy methyl cellulose, Croscarmellose sodium, Low substituted hydroxyl 
cellulose. 
1.4. TABLET EVALUATION TESTS 
The quantitative evaluation and assessment of a tablet’s chemical, physical 
and bioavailability properties are important in the design of tablets and to monitor 
product quality. These properties are important since chemical breakdown or 
interactions between tablet components may alter the physical tablet properties, and 
greatly affect the bioavailability of the tablet system8 
There are various standards that have been set in the various pharmacopoeias 
regarding the quality of pharmaceutical tablets. These include the diameter, size, 
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shape, thickness, weight, hardness, disintegration and dissolution characters. The 
diameters and shape depends on the die and punches selected for the compression of 
tablets.  
1.4.1. General Appearance 
The general appearance of tablets, its visual identity and overall elegance is 
essential for consumer acceptance, control of lot to lot uniformity and general tablet to 
tablet uniformity and for monitoring the production process. The control of general 
appearance involves measurement of attributes such as a tablets size, shape, color, 
presence or absence of odor, taste, surface textures, physical flaws and consistency. 
1.4.1.1. Shape and size 
The shape and dimensions of compressed tablets are determined by the type of 
tooling during the compression process. At a constant compressive load, tablet 
thickness varies with changes in die fill, particle size distribution and packing of 
powder mix being compressed and with tablet weight, while with a constant die 
fill,thickness varies with variation in compressive load. The thickness of individual 
tablets may be measured with a micrometer, which permits accurate measurements 
and provides information of the variation between tablets. Tablet thickness should be 
controlled within a ± 5% variation of a standard value. The physical dimensions of the 
tablet along with the density of the material in the tablet formulation and there 
proportions, determine the weight of the tablet. The size and shape of the tablet can 
also influence the choice of tablet machine to use, the best particle size for 
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granulation, production lot size that can be made, the best type of tableting processing 
that can be used, packaging operations and the cost of production. 
The USP has provided limits for the average weight of uncoated compressed 
tablets. 
Table1 :Weight variation requirements as per USP 
Average weight % difference 
130 mg or less 10 
More than 130 mg through 324mg 7.5 
More than 324mg  5 
 
1.4.1.2 Organoleptic properties 
Color is a vital means of identification for many pharmaceutical tablets and is 
also usually important for consumer acceptance. The color of the product must be 
uniform within a single tablet, from tablet to tablet and from lot to lot. Non uniformity 
of coloring not only esthetic appeal but could be associated by the consumer with non 
uniformity of content and general poor product quality. Reflectance 
spectrophotometry, tristimulus colorimetric measurements and micro reflectance 
photometer have been used to measure color uniformity and gloss on tablet surface. 
Odor may also be important for consumer acceptance of tablets and can 
provide an indication of the quality of tablets as the presence of an odor in a batch of 
tablets could indicate a stability problem, such as the characteristic odor of acetic acid 
in degrading aspirin tablets.Taste is also important for consumer acceptance of certain 
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tablets(chewable tablets)and many companies utilize taste panels to judge the 
preference of different flavors and flavor levels in the development of a product 
1.4.2. Content Uniformity 
The content uniformity test is used to ensure that every tablet contains the 
amount of drug substance intended with little variation among tablets within a batch. 
Due to increased awareness of physiological availability, the content uniformity test 
has been included in the monographs of all coated and un coated tablets and all 
capsules intended for oral administration where the range of size of the dosage form 
available include 50 mg or smaller sizes. Tablet monographs with a content 
uniformity requirement do not have weight variation requirements. For content 
uniformity test, representative samples of 30 tablets are selected and 10 are assayed 
individually. At least 9 must assay within ± 15% of the declared potency and non may 
exceed ±25 % 
1.4.3. Mechanical Strength of Tablets 
The mechanical strength of a tablet provides a measure of the bonding 
potential of the material concerned and this information is useful in the selection of 
excipients. An excessively strong bond may prevent disintegration and subsequent 
dissolution of a drug. Weak bonding characteristics may limit the selection and/or 
proportion of excipients, such as lubricants, that would be added to the formulation. 
The mechanical properties of pharmaceutical tablets are quantifiable by the friability, 
hardness or crushing strength, crushing strength friability values, tensile strength and 
brittle fracture index9 
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1.4.4 Friability 
Friction and shock are the forces that most often cause tablets to chip, cap or 
break. The friability test is closely related to tablet hardness and is designed to 
evaluate the ability of the tablet to withstand abrasion in packaging, handling and 
shipping. It is usually measured by the use of the Roche friabilator. A number of 
tablets are weighed and placed in the apparatus where they are exposed to rolling and 
repeated shocks as they fall 6 inches in each turn within the apparatus. After 4 min of 
this treatment or 100 revolutions the tablets are weighed and the weight compared 
with the initial weight. The loss due to abrasion is the measure of tablet friability. The 
value is expressed as percentage. A maximum weight loss of not more than 1 % of the 
weight of the tablets being used during the friability test is considered generally 
acceptable and any broken or smashed tablets are not picked up. Normally, when 
capping occurs, friability values are not calculated. A thick tablet may have fewer 
tendencies to cap where as thin tablets of large diameter often show extensive 
capping, thus indicating that tablets with greater thickness have reduced internal 
stress. 
1.4.5. Hardness or Crushing Strength 
The resistance of tablets to capping, abrasion or breakage under conditions of 
storage, transportation and handling before usage depends on its hardness. The small 
and portable hardness tester was manufactured and introduced by Monsanto. The 
instrument measures the force required to break the tablet when the force generated 
by a coil spring is applied diametrally to the tablet.  Hardness, which is now more 
appropriately called crushing strength determinations are made during tablet 
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production and are used to determine the need for pressure adjustment on tablet 
machine. If the tablet is too hard, it may not disintegrate in the required period of time 
to meet the dissolution specifications if it is too soft, it may not be able to withstand 
the handling during subsequent processing such as coating or packing and shipping 
operations. The force required to break the tablet is measured in kilograms and a 
crushing strength of 4 Kg is usually considered to be the minimum for satisfactory 
tablets. Oral tablets normally have a hardness of 4 to 10 kg. Tablet hardness has been 
associated with other tablet properties such as density and porosity. Hardness 
generally increases with normal storage of tablets and depends on the shape, chemical 
properties, binding agent and pressure applied during compression.  
1.4.6. Tensile Strength 
A non-compendial method of measuring the mechanical strength of tablets 
that is now widely used id the tensile strength. This is the force required to break a 
tablet in a diametral compression test. The radial tensile strength, T, of thetablets can 
be calculated from the equation 
T=2F/pdH 
Where F is the load needed to break the tablet, and d and H are the diameter 
and thickness respectively. Several precautions must be taken when using the 
equation. Various factors e.g. test conditions, deformation properties of the material, 
adhesion conditions between compact and its support and tablet shape may influence 
the measurements of the tensile strength. 
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1.4.7. Disintegration 
For a drug to be absorbed from a solid dosage form after oral administration, it 
must first be in solution, and the first important step toward this condition is usually 
the break-up of the tablet; a process known as disintegration. The disintegration is a 
measure of the time required under a given set of conditions for a group of tablets to 
disintegrate into particles which will pass through a 10 mesh screen. Generally, the 
test is useful as a quality assurance tool for conventional dosage forms. The 
disintegration test is carried out using the disintegration tester which consists of a 
basket rack holding 6 plastic tubes, open at the top and the bottom, the bottom of the 
tube is covered by a 10-mesh screen. The basket is immersed in a bath of suitable 
liquid held at 370c, preferably in a 1L beaker. For compressed uncoated tablets, the 
testing fluid is usually is water at 37 0 c but some monographs direct that simulated 
gastric fluid be used. If one or two tablets fail to disintegrate, the test is repeated using 
12 tablets. For most uncoated tablets, the BP requires that the tablets disintegrate in 15 
min(although it varies for some uncoated tablets) while for coated tablets, up to 2 h 
may be required. The individual drug monographs specify the time disintegration 
must occur to meet the Pharmacopoeial standards. 
1.4.8. Dissolution 
Dissolution is the process by which a solid solute enters a solution. In the 
pharmaceutical industry, it may be defined as the amount of drug substance that goes 
into solution per unit time under standardized conditions of liquid/solid interface, 
temperature and solvent composition. Dissolution is considered as one of the most 
important quality control tests performed on pharmaceutical dosage forms and is now 
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developing into a tool for predicting bio availability, and in some cases, replacing 
clinical studies to determine bio equivalence. Dissolution behavior of drugs has a 
significant effect on their pharmacological activity. In fact, a direct relationship 
between in vitro dissolution rate of many drugs and their bio availability has been 
demonstrated and is generally referred to as in vitro-in vivo correlation, IVIVC. 
For many drugs, particularly those that are poorly soluble in the gastric fluid, 
the rate limiting step in the absorption process is the dissolution rate and a dissolution 
rate determination can therefore be a useful guide to comparative bio availability. 
Since drug absorption and physiological availability depend on the availability of the 
drug substance in a dissolved state, suitable dissolution characteristics are important 
property for a satisfactory tablet. The dissolution test measures the amount of time 
required for certain percentage of the drug substance in a tablet to go into solution 
under a specified set of conditions. It describes a step towards physiological 
availability of the drug substance, but it is not designed to measure the safety or 
efficacy of the tablet being tested. It provides invitro control procedure to eliminate 
variation among production batches. The dissolution medium must be aqueous and 
the pH of the medium should be controlled and should simulate invivo conditions. The 
dissolution medium should be 0.1 M HCL and pH 6.8 buffer to simulate the bio 
logical extremes. The possible role of bile salts in absorption of highly in soluble 
drugs suggests the inclusion of physiological concentrations of sodium taurocholate in 
the mildly acid or alkaline media. Studies have shown that low agitation must be used 
(i.e. in the order of 50 rpm)and that the tablet must not be subjected to abrasion in 
keeping with the mild agitation in the gastrointestinal tract. 
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Fig. 1:Schematic diagram of the dissolution process 
Dissolution kinetics is important in determining the bio availability of a drug. 
Levy and some other workers reported that the dissolution rate controls the rate of 
buildup of certain drugs in the blood stream. It was thus recognized that in-vitro 
dissolution kinetics provides useful information on the availability of drugs and their 
subsequent therapeutic effects in vivo. This lead to the inclusion of dissolution tests in 
the United States NF XIII (1970) and USP XVIII (1970)monographs for one capsule 
and 12 tablet preparations. 
1.4.8.1. Discriminative pH method for dissolution of tablets. 
Immediate release dosage forms are designed to allow drugs to dissolve freely 
in the GI contents, with no intention of prolonging the dissolution or absorption of 
drugs upon administration. IR products could be rapidly dissolving or slowly 
dissolving depending on the intrinsic dissolution rate of the drug substances. For a 
rapidly dissolving product, more than 85 % of API is expected to dissolve within 30 
min in ≤ 900 ml of aqueous medium. 
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According to FDA draft guidance document, entitled “Waiver of In-Vivo 
Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage 
Forms Containing Certain Active Moieties/Active Ingredients Based on a 
Biopharmaceutical Classification System” for waivers of an in-vivo relative 
bioavailability study, dissolution should be greater than 85 % in 30 min in the three 
recommended dissolution media (acidic media, such as 0.1 N HCL or Simulated 
Gastric Fluid USP without enzymes, a pH 4.5 buffer and a pH 6.8 buffer or Simulated 
Intestine Fluid USP without enzymes). For waivers of in-vivo bio equivalent, test and 
reference products should exhibit similar dissolution profiles under the dissolution test 
conditions defined for rapidly dissolving products. 
  Literature review 
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2. LITERATURE REVIEW 
2.1PAST WORK ON TIANEPTINE SODIUM 
Fuad Lechin et al., 2009, investigated the effects of tianeptine, a drug which 
enhances 5-HT uptake during the oral glucose tolerance test. They found that the drug 
triggered significant and sustained insulin rises which were opposite to the plasma 
glucose decreases. The fact that significant nor adrenaline/adrenaline (NA/Ad) plasma 
ratio paralleled insulin rises throughout the test is consistent with the excitatory role 
played by the peripheral neural sympathetic activity11 
 
Sevgi Tatar and Zeynep, 2008, developed a method which involves formation of 
colored chloroform extractable ion-pair complexes of tianeptine with bromophenol 
blue (BPB), bromocresol green (BCG), bromothymol blue (BTB) and methyl orange 
(MO) in acidic medium. Beer’s law is obeyed in the concentration ranges 3.0—12.0, 
4.0—16.0, 4.0—14.0 and2.0—10.0mgml_1 with BPB, BCG, BTB and MO, 
respectively. The detection limit of tianeptine was found to be1.8mgml_1 for BPB, 
2.0 for BCG, 2.0mgml_1 for BTB and 1.0mgml_1 for MO12 
 
Dresse et al., 1988, studied influence of a test meal on the absorption and disposition 
of tianeptine (Stablon), a new antidepressant, was investigated in 12 healthy subjects 
in a two-way, randomized, open cross-over study. Single 12.5-mg oral doses of 
tianeptine were administered following a night of fasting or immediately after a 
standardized breakfast. When subjects received tianeptine under fasting conditions the 
lag time before absorption onset, and the time of the maximum plasma concentration 
were 0.55 +/- 0.26 hours and 1.29 +/- 0.29 hours, respectively. The maximum plasma 
concentration was 322 +/- 44 ng/mL, and the total area under the curve 994 +/- 248 
ng/hr/mL13  
 
Loo et al., 1990, demonstrated its ant depressive clinical efficacy in several double-
blind versus reference drug trials. A multicentre open trial, including depressed 
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patients enabled us to evaluate the safety of tianeptine and to control the maintenance 
of the therapeutic efficacy in the course of its long-term prescription14 
Dalery et al., 2001, compared the efficacy and acceptability of tianeptine vs placebo 
in the long-term treatment of unipolar major recurrent depression, 268 hospitalized 
and ambulatory patients meeting DSM III-R criteria for major depression with a 21-
item Hamilton depression rating scale (HDRS) score ≥ 17 and at least one episode in 
the previous 5 years received tianeptine in a 6-week multicenter open study.15 
Wagstaff and Ormrod DSpencer , 2001, studied Tianeptine as an antidepressant 
agent with a novel neurochemical profile. It increases serotonin (5-
hydroxytryptamine, 5-HT) uptake in the brain (in contrast with most antidepressant 
agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective 
serotonin reuptake inhibitors (SSRIs) and in contrast with most tricyclic 
antidepressant agents, tianeptine does not appear to be associated with adverse 
cognitive, psychomotor, sleep, cardiovascular or bodyweight effects and has a low 
propensity for abuse16 
Doaa Ahmed El-Setouhy et al., 2008, formulated orodispersible film(s) of the 
antidepressant drug tianeptine sodium to enhance the convenience and compliance by 
the elderly and pediatric patients. The novel film former, lycoat NG73 (granular 
hydroxypropyl starch), along with different film-forming agents (hydroxypropyl 
methyl cellulose, hydroxyethyl cellulose, and polyvinyl alcohol), in addition to three 
film modifiers, namely, maltodextrin, polyvinyl pyrrolidone K90 and lycoat RS780 
(pregelatinized hydroxypropyl starch) were evaluated. Eight formulae were prepared 
by the solvent-casting method, and were evaluated for their in vitro dissolution 
characteristics, in vitro disintegration time, and their physico-mechanical properties17 
Michaela Bulaceanu et al., 1988, examined photo chemically induced fluorescence 
(PIF) properties of tianeptine and some of its metabolites were investigated in acidic 
(pH 2.3) water–alcohol mixtures at room temperature. Two PIF methods were 
developed, including bulk solution and flow injection analysis (FIA). Linear 
calibration plots were established over a concentration range of more than one order 
of magnitude. Limits of detection ranged from 15 ng ml–1 for FIA-PIF to 25 ng ml–1 
in bulk solution. The RSDs were between 3 and 5%. The PIF methods were applied to 
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the determination of tianeptine in a pharmaceutical preparation with recoveries 
varying from 96 to 106% in bulk solutions and from 98 to 106% for FIA-PIF18 
Niederhofer et al., 2003, observed twelve male children (7.3 ± 3.3 years) with autistic 
disorder, diagnosed by ICD-10 criteria, completed a placebo-controlled, double-blind 
crossover trial of tianeptine, which lasted for 12 weeks. Subjects were included in the 
study if their eye contact and expressive language was inadequate for their 
developmental level. Subjects had not tolerated or responded to other 
psychopharmacological treatments (neuroleptics, methylphenidate, clonidine or 
desipramine).Tianeptine were modestly effective in the short-term treatment of 
irritability in some children with autistic disorder19 
Salvadori et al., 1990, studied the disposition of the antidepressant tianeptine and its 
MC5 metabolite (pentanoic acid analogue of tianeptine) was studied following a 
single 12.5 mg oral dose of tianeptine sodium salt in 20 patients with chronic renal 
failure. In 12 patients (group I) having a creatinine clearance of less than 19 mlmin−1 
the pharmacokinetics parameters for tianeptine and MC5 metabolite were determined 
and compared with those obtained in a matched control group (group II). The other 8 
patients (group III) were functionally anephric and were studied during 1 dialysis to 
assess the haemodialysis clearances of tianeptine and MC5 metabolite. The 
comparison between groups I and II showed that renal failure did not appear to affect 
the disposition of parent tianeptine20 
Tatar Ulu and Sevgi, 2007, used sensitive and selective high-performance liquid 
chromatographic method has been developed for the determination of tianeptine (Tia) 
in tablets. The method is based on derivatization of Tia with 4-chloro-7-
nitrobenzofurazan (NBD-CI). A mobile phase consisting of acetonitrile-10 mM 
orthophosphoric acid (pH 2.5, 77 + 23) was used at a flow rate of 1 mL/min on a C1a 
column. The Tia-NBD derivative was monitored using a fluorescence detector, with 
emission set at 520 nm and excitation at 458 nm. Gabapentin was selected as an 
internal standard. Linear calibration graphs were obtained in the concentration range 
of 45-300 ng/mL The lower limit of detection (LOD) was 10 ng/mL at a signal-to-
noise ratio of 4. The lower limit of quantitation (LOO) was 45 ng/mL21 
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Vadachkoria et al., 2009, surveyed a total of 24 patients (male volunteers), 
consumers of opiates in the past and suffering from Tianeptine abuse, were under 
clinical observation. The age range of patients was from 21 to 33 years. Tianeptine 
consumption history was 5 months duration on the average. The daily dose of 
preparation was 40 tablets (500 mg intravenous injections on the average). Patients 
used Tianeptine in combination with antihistamines (Promethazine, Suprastin). 
Research was carried out with the use of clinical, psychological and laboratory 
methods22 
Grasela and Fiedler, 2002, predicted the ability of population pharmacokinetic 
parameters of tianeptine, obtained from a mixed effect analysis of pre-marketing 
pharmacokinetic studies, was evaluated using tianeptine plasma concentrations 
obtained during a large multi-center post-marketing surveillance study23 
Daniel Ginestet, 1997, studied the efficacy of tianeptine in the treatment of major 
depressive episodes was assessed in three double-blind placebo-controlled studies. In 
a first double-blind study comparing tianeptine (37.5 mg/day) with placebo, 126 
patients with Major Depression or a Depressed Bipolar Disorder were treated for 42 
days, 60% of these patients fulfilled DSM-III-R criteria for melancholia24 
Salvadori et al., 1990, applied a balanced 3 way cross-over study involving 12 young 
healthy volunteers (6 men and 6 women) was used to determine the pharmacokinetic 
parameters of the antidepressant tianeptine following a single dose administered by 
oral and intravenous route. The influence of alcohol on the pharmacokinetics of 
tianeptine when given per os was also investigated. Kinetic parameters of metabolite 
MC5, the C5 side chain beta–oxidation product of tianeptine, were simultaneously 
determined25 
Royer et al., 1988, conducted a study by following oral administration in the fasting 
healthy subject, the mean maximum concentration of tianeptine is 334 +/-79 ng/ml. 
Absorption of tianeptine from the tablet form is rapid and complete. Maximum 
plasma concentration is obtained by the first hour following administration (0.94 +/- 
0.47 h). Absolute bioavailability is 99 +/- 29%. Tianeptine is thus rapidly and 
completely absorbed in the tablet form and is not subject to first-pass effect. 
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Distribution of tianeptine in the body is characterized by the following: its rapidity, 
the mean distribution half-life being about 0.7 h, its limited extent, the apparent 
volume of distribution being about 0.8 L/kg (0.77 +/- 0.31 L/kg), and protein binding, 
which averages 93.8 +/- 2.4%. Elimination of tianeptine is characterized by a short 
mean half-life of 2 h 30 min (2.5 +/- 1.1 h) and by renal excretion of 0.4 ml/min (0.4 
+/- 0.4 ml/min). Tianeptine is extensively metabolized26 
Guillem and Lepine, 2003, reported on a tianeptine dependence lasting for eighteen 
months in a 42 year old patient. The patient had a previous history of addiction to 
opiates, amineptine, cocaine and alcohol. He also had a family history of addiction to 
alcohol and opiates. Tianeptine was prescribed for a major depressive disorder. The 
patient alleged a "flash sensation" like with heroin since the very first doses with a 
physical and psychological well-being sensation, better psychomotor performances 
and transient mood elation. His addiction to tianeptine was immediate and heavy27 
Koen Schruers and Eric Griez, 2004, suggested that increased 5-HT availability is 
important for the anti-panic effect of serotonergic drugs and in maintaining the 
response to selective serotonin reuptake inhibitors (SSRIs). Tianeptine is an 
antidepressant with 5-HT reuptake enhancing properties (i.e. the opposite 
pharmacological profile to that of SSRIs). Therefore, no effect would be expected in 
panic disorder. The aim of the present study was to compare the effect of tianeptine 
with that of paroxetine, a selective 5-HT reuptake inhibitor with demonstrated 
efficacy in panic disorder, on the vulnerability to a laboratory panic challenge in panic 
disorder patients28 
Guelfi, et al., 1989, conducted a study on 265 adult outpatients with dysthymic 
disorder (DSM-III) associated with clinically manifest anxiety (according to FDA 
criteria) were included in a multicenter, randomized double-blind study. The trial 
consisted of three phases: placebo pretreatment phase and inclusion in the trial, 
treatment phase, placebo post treatment phase. Patients were treated in mono therapy 
for 42 days with a mean dosage of 3 tablets per day corresponding to 37.5 mg/day of 
tianeptine or 75 mg/day of amitriptyline respectively29 
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Mathieu Boiret et al., 2011, developed a near infrared (NIR) method for 
determination of tablet potency of active pharmaceutical ingredient (API) in a 
complex coated tablet matrix. The calibration set contained samples from laboratory 
and production scale batches. The reference values were obtained by high 
performance liquid chromatography (HPLC) and partial least squares (PLS) 
regression was used to establish a model. The model was challenged by calculating 
tablet potency of two external test sets. Root mean square errors of prediction were 
respectively equal to 2.0% and 2.7%30 
Hantzberg et al., 1987, concerned the use of a new antidepressant, tianeptine, as a 
treatment of depressive and/or amotival syndrome, in 30 drug addicts, detoxified from 
opiates. From a thymoanaleptic point of view, 85% of the patients exhibit a positive 
result after 28 days of treatment with 37.5 mg/day. These good results are confirmed 
by the evolution of the Hamilton Depression Rating Scale global score, which 
significantly decreases from D0 to D14 and from D14 to D28. The acceptability of the 
antidepressant is good. Anticholinergic side-effects are very uncommon. Tianeptine 
appears devoid of any obvious psycho stimulant or sedative effect31 
 
2.4. PAST WORK ON IMMEDIATE RELEASE TABLETS 
 
Abhay Gupta et al., 2009, investigated correlation between disintegration and 
dissolution for immediate release tablets containing a high solubility drug and to 
identify formulations where disintegration test, instead of the dissolution test, may be 
used as the acceptance criteria based on International Conference on Harmonization 
Q6A guidelines. A statistical design of experiments was used to study the effect of 
filler, binder, disintegrating agent, and tablet hardness on the disintegration and 
dissolution of verapamil hydrochloride tablets32 
Biljana Govedarica et al., 2011, demonstrated the best tablet properties with coated 
paracetamol (mass of tablets, diameter, height and mechanical strength, friability 
RSD<2%).Furthermore, coated paracetamol in combination with both investigated 
superdisintegrants such as Vivasol® and Polyplasdone® XL-10 shows faster 
disintegration time and dissolution rate in comparison to paracetamol for direct 
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compression. Eventually, the major advantages of the formulation with coated 
paracetamol for industrial production are decrease of friability and superiority in 
terms of flowability, compressibility, quick disintegration and dissolution. Regarding 
the results, coating of PAR particles is beneficial for the manufacturing of tablets with 
immediate release33 
Kyriacos Soula and Dimassi Hani, 2009, studied the critical formulation/process 
factors were the type and concentration of microcrystalline cellulose, the ratio of 
lactose to microcrystalline cellulose, the concentration of croscarmellose, and the 
compression force. A two-step approach was implemented. First an optimization 
study was performed to determine the type of microcrystalline cellulose and its ratio 
to lactose. Subsequently, a final optimization formulation study was performed based 
on the results obtained in the preliminary study. Data were analyzed using the SPSS 
15 (Statistical Software for Social Sciences). The differences in means between the 
formulation and the targeted product34 
Parikh, 2010, attempted to develop solid oral formulations of Telmisartan which can 
be prepared using less complicated and expensive processes and fulfill all 
prerequisites for pharmaceutical use, i.e. long-lasting stability of the formulation 
under different climatic conditions and sufficient solubility of the active substance for 
sufficient gastrointestinal absorption in the slightly acidic and neutral pH region. 
Preferably, the formulations should have immediate release characteristics and a 
dissolution showing no essential pH dependency within the physiological relevant pH 
interval of the gastrointestinal tract35 
Huet al., 2006, optimized the formulation of immediate release tablet. The immediate 
release tablet was prepared by using dry granules. The preparation was optimized by 
using orthogonal design which took the flow property of granules, the hardness, the 
disintegrating time and the dissolution rate of the tablet as indices. The optimized 
formulation contained 40% microcrystalline cellulose, 10% sodium carboxymethyl 
starch and 15% dextrin. The hardness disintegrating time and T50 of the tablet were 
4.5 kg, 3 min, 5 min respectively36 
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2.5. PAST WORK DONE ON EXCIPIENTS 
Gohel et al., 2007, used superdisintegrants are sodium starch glycolate, crospovidone, 
and croscarmellose sodium. Like diluents, each superdisintegrant has strengths and 
weaknesses. In the present investigation, the preparation and evaluation of co 
processed disintegrant containing crospovidone and sodium starch glycolate was 
explored. The reasons for the selection of crospovidone are as follows: better 
compressibility compared with other superdisintegrants, high capillary activity, 
pronounced hydration capacity, and little tendency to form gels. Moreover, the rate 
and extent of liquid uptake and swelling of crospovidone (Polyplasdone XL 10) are 
not reduced in 0.1 N hydrochloric acid when compared with aqueous medium. The 
aqueous medium (water) represents disintegration medium and 0.1 N HCl represents 
gastric environment. Sodium starch glycolate was chosen because of its high swelling 
capacity. Moreover, the disintegrant efficiency of sodium starch glycolate is 
unimpaired by the presence of hydrophobic excipients such as lubricants37 
Ganesh Chaulang et al., 2008, investigated enhancement of the dissolution profile of 
furosemide using solid dispersion (SD) with crospovidone (CPV) by using kneading 
technique. 1:1 (w/w) and 1:2 (w/w) solid dispersions were prepared by kneading 
method using solvent water and ethanol in 1:1 ratio38 
Phake and Anderson, 1990, studied the effect of crospovidone on the characteristics 
of wet granulated acetaminophen was investigated. Power blends of acetaminophen 
and crospovidone were wet granulated using hydroxypropyl methylcellulose as the 
binder and water as the granulating liquid. The sieve analysis data showed that as the 
level of crospovidone in the powder blend increased, there was an increase in the 
amount of fines in the particle distribution of the dried granulations. The bulk 
densities of formulae containing a higher level of crospovidone were generally lower 
although no clear trend was seen for the tap density values.. The results of this study 
indicate that an interaction of both mechanisms may be responsible for the effect of 
crospovidone on the characteristics of wet granulated acetaminophen39 
Sangmesh Torne et al., 2010, studied fast disintegrating tablets of taste masked 
ondansetron hydrochloride were prepared by direct compression method with a view 
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to enhance patient compliance. Taste masking was done by complexing ondansetron 
hydrochloride with eudragit EPO in ratio 8:2. Two superdisintegrant i.e. crospovidone 
and croscarmellose sodium were used in different combination ratio40. 
Suhas et al., 2010, developed mouth dissolving tablets of losartan potassium were 
design with a view to enhance the patient compliance and provide a quick onset of 
action. Losartan potassium is an angiotensin receptor antagonist, used in the 
management of hypertension. It has low bioavailability due to its first pass 
metabolism. Hence the main objective of the study was to formulate mouth dissolving 
tablets of losartan potassium to achieve a better dissolution rate and further improving 
the bioavailability of the drug. Mouth dissolving tablets prepared by direct 
compression and using super disintegrants like Polyplasdone XL 10, Croscarmellose 
sodium and Explotab in different concentration.41 
Ferrero et al., 1997, studied the efficiency of croscarmellose sodium (Ac-Di-Sol®) in 
a direct compression formulation containing a poorly water soluble drug at high 
dosage was investigated. An experimental design with two variables, applied pressure 
and concentration of Ac-Di-Sol®, allowed the evaluation of micro structural, 
mechanical and disintegration properties of the tablets. Tablet properties evaluated 
were affected by both variables, while compression parameters were essentially 
dependent on applied pressure42 
Piyush Patelet al., 2009, determined if a solid dispersion of furosemide in sodium 
starch glycolate (SSG) would enhance the dissolution properties of the drug. Solid 
dispersion of furosemide in SSG was prepared in ratios of 1:1 and 1 (furosemide):2 
(SSG) by kneading method Tablets containing the solid dispersion were formulated 
and their dissolution characteristics compared with commercial furosemide tablets43 
Vineet Bhardwajet al., 2010, aimed to prepare fast disintegrating tablets of 
Amlodipine Besylate by using different disintegrants and to evaluate the effect of 
increasing Amlodipine Besylate load on the characteristics of fast‐disintegrating 
sublingual tablets for the potential emergency treatment of angina and hypertension. 
The superdisintegrant used in this study were Kollidon CL, Ac‐Di‐Sol and Sodium 
Starch Glycolate in varying concentrations (2%, 4%, 6%) 44 
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3. AIM & OBJECTIVE 
The main aim of the current study was to formulate Tianeptine sodium tablets and to 
evaluate. 
 Immediate release tablets are most widely used dosage forms. These products are 
designed to disintegrate in the stomach followed by their dissolution in the fluids of the 
gastro intestinal tract. 
 Tianeptine is a selective serotonin reuptake enhancer (SSRE) drug used for treating 
major depressive episodes (mild, moderate, or severe). It is having a half-life of 2.5 h and 
used at a dose of 12.5 mg. 
Currently, Tianeptine is approved in France and manufactured and marketed by 
Laboratoires Servier SA, it is also marketed in a number of other European countries under 
the trade name "Coaxil" as well as in Asia and Latin America as "Stablon" and "Tatinol" but 
it is not available in the UK. 
The objective of the study was,  
 To develop tianeptine sodium immediate release tablets to achieve faster dissolution 
to match the innovator product Stablon 12.5 mg. 
 Another objective of the study is to evaluate dissolution profiles of these tablets in 
discriminating dissolution mediums to ensure its bioequivalence. 
 
Plan of work 
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4. PLAN OF WORK 
 Literature survey 
 Selection of materials and methodology 
 Compatibility study of drug with various excipients using DSC. 
 Preparation of Tianeptine sodium immediate release tablets 
 Evaluation of tablet granules and tablets prepared for the following: 
Precompression parameters: 
 Angle of repose 
 Bulk density 
 Tapped density 
 Hausner’s ratio 
 Carr’s compressibility index 
         Post compression parameters: 
 Hardness 
 Disintegration time 
 Content uniformity 
 Friability 
 Weight variation 
 In vitro dissolution studies 
 Drug content estimation by HPLC 
 Accelerated stability studies 
 
Drug and Excipients Profile 
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5. DRUG PROFILE& EXCIPIENTS PROFILE 
5.1 DRUG PROFILE 
Chemical name: [3-chloro-6-methyl-5, 5-dioxo-6, 11-dihydro-(c, f)-dibenzo-(thiazepine)- 
11-yl) amino]-7 heptanoic acid, sodium salt.  
Structure: 
 
 
Fig 2: Structureof Tianeptine 
Molecular formula: C21H24ClN2NaO4S 
Molecular weight: 458.9 g/mol 
Strength: 12.5 mg 
Description: white coated tablet. 
Pharmaceutical Classification: Antidepressant  
Bioavailability: 70-99% 
Metabolism: Hepatic 
Half life: 2.5 h 
Excretion: renal 
Mechanism of action:   Initial studies found that upon acute and sustained administration, 
tianeptine decreased the extracellular levels of serotonin. However tianeptine has low affinity 
for serotonin transporters, so this effect appears to be indirect However, co administration of 
tianeptine and fluoxetine inhibited tianeptine's effect on long-term potentiation in 
Drug and Excipients Profile 
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hippocampal CA1 area. In contrast to SSRIs and tricyclic antidepressants, tianeptine 
modestly enhances the mesolimbic release of dopamine, but it is also unclear how this occurs 
because tianeptine itself has no effect on dopamine transporters, nor does it affect D1, D2, 
D3, D4 and D5 receptors 
 Dosage and administration: 1 tablet 3 times a day before the main meals of the day. 
 Adverse Effects:Gastralgia, abdominal pain, dryness of the mouth, anorexia, nausea, 
vomiting, flatulence Insomnia, drowsiness, nightmares, asthenia Tachycardia, extra systole, 
precordialgia Dizziness, headaches, faintness, trembling, upsets Respiratory discomfort, 
tightness of the throat Myalgia, lumbago  
 Pharmacokinetics: Gastro intestinal absorption is rapid and complete. Distribution is rapid 
and is associated with a high level of protein binding (approx. 94%). Molecule is extensively 
metabolized in the liver by the processes of beta-oxidation and N- demethylation. Elimination 
is characterized by a short terminal half life of 2.5 hr, only a very slight excretion of parent 
compound (8%) via the kidneys and an essentially renal route of excretion for the 
metabolites. 
 In elderly subjects: Pharmacokinetic studies performed in chronically treated elderly 
patients (age over 70 yrs) demonstrated an increase of 1 hr in the elimination half life. 
 In subjects with hepatic insufficiency: Studies have shown that the effects of chronic 
alcoholism on the pharmacokinetic parameters are negligible, even when alcoholism is 
associated with cirrhosis of the liver. 
 In subjects with renal insufficiency: Studies have shown an increase of 1 hr in the 
elimination half life. 
5.2. EXCIPIENTS PROFILE 
5.2.1. Talc 
Nonproprietary names 
BP: Purified Talc 
Drug and Excipients Profile 
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JP: Talc 
PhEur: Talc 
USP: Talc 
Synonyms 
Altalc, E553b, hydrous magnesium calcium silicate, hydrous magnesium silicate, Imperial, 
Luzenac Pharma, magnesium hydrogen metasilicate, MagsilOsmanthus, Magsil Star, 
powdered talc, purified French chalk, Purtalc, soapstone, steatite, Superiore, talcum. 
 Chemical Name 
Talc  
 Empirical formula 
Mg6 (Si2O5)4(OH)4 
 Description 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline 
powder. It adheres readily to the skin and is soft to the touch and free from grittiness. 
 Functional category 
Anticaking agent, glidant, tablet and capsule diluent, tablet and capsule lubricant 
Table 2: Uses of talc 
Use Concentration (%) 
Dusting powder 90.0-99.0 
Glidant and tablet lubricant 1.0-10.0 
Tablet and capsule diluent 5.0-30.0 
 
 Applications in pharmaceutical formulation or technology 
 Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent. 
 It is widely used as a dissolution retardant in the development of controlled-release 
products. 
 Talc is also used as a lubricant in tablet formulations. In a novel powder coating for 
extended-release pellets,and as an adsorbant. 
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 Talc is used to clarify liquids and is also used in cosmetics and food products, mainly 
for its lubricant properties. 
 Stability and storage conditions 
Talc is a stable material and may be sterilized by heating at 160˚C for not less than 1 
hour. It may also be sterilized by exposure to ethylene oxide or gamma irradiation. Talc 
should be stored in a well-closed container in a cool, dry place. 
 Incompatibilities 
Incompatible with quaternary ammonium compounds10 
 
5.2.2. Magnesium stearate 
Nonproprietary names 
BP: Magnesium Stearate 
JP: Magnesium Stearate 
PhEur: Magnesium Stearate 
USP-NF: Magnesium Stearate 
Synonyms 
Dibasic magnesium stearate, magnesium distearate, magnesiistearas, magnesium 
octadecanoate, octadecanoic acid, magnesium salt, stearic acid, magnesium salt, Synpro 90 
Chemical name 
Octadecanoic acid magnesium salt 
Empirical formula  
C36H70MgO4 
Molecular weight 
591.24 g/mol 
Structural formula 
[CH3 (CH2)16COO] 2Mg 
Functional category 
Tablet and capsule lubricant 
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Description 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic taste. The 
powder is greasy to the touch and readily adheres to the skin. 
Applications in pharmaceutical formulation or technology 
 It is widely used in cosmetics, foods, and pharmaceutical formulations.  
 It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25%- 5.0% w/w. 
  It is also used in barrier creams.  
Stability and storage conditions 
Magnesium stearate is stable and should be stored in a well closed container in a cool, 
dry place. 
Incompatibilities 
Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, some 
vitamins, and most alkaloidal salts. 
5.2.3. Mannitol 
 Nonproprietary names 
BP: Mannitol 
JP: D-Mannitol 
PhEur: Mannitol 
USP: Mannitol 
Synonyms 
Cordycepic acid, C*PharmMannidex, E421, Emprove, manna sugar, D mannite, 
mannite, mannitolum, Mannogem, Pearlitol 
Chemical name 
D-Mannitol 
Empirical formula 
C6H14O6 
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Molecular weight 
182.17 g/mol 
Structural formula 
 
Fig 3: Structure of Manitol 
Functional category 
Diluent, plasticizer, sweetening agent, tablet and capsule diluent, therapeutic agent, 
tonicity agent 
Description 
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is isomeric 
with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or free flowing 
granules. It has a sweet taste, approximately as sweet as glucose and half as sweet as sucrose, 
and imparts a cooling sensation in the mouth. Microscopically, it appears as orthorhombic 
needles when crystallized from alcohol. Mannitol shows polymorphism. 
Applications in pharmaceutical formulation or technology 
 In pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in 
tablet formulations, where it is of particular value since it is not hygroscopic and may 
thus be used with moisture-sensitive active ingredients. 
 Mannitol may be used in direct-compression tablet applications for which the granular 
and spray-dried forms are available, or in wet granulations. Granulations containing 
mannitol have the advantage of being dried easily.  
 Specific tablet applications include antacid preparations, glyceryltrinitrate tablets, and 
vitamin preparations. 
 Mannitol is commonly used as an excipient in the manufacture of chewable tablet 
formulations because of its negative heat of solution, sweetness, and mouth feel. 
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  In lyophilized preparations, mannitol (20–90% w/w) has been included as a carrier to 
produce a stiff, homogeneous cake that improves the appearance of the lyophilized 
plug in a vial. 
 Mannitol has also been used to prevent thickening in aqueous antacid suspensions of 
aluminum hydroxide (<7% w/v). 
  It has been suggested as a plasticizer in soft-gelatin capsules, as a component of 
sustained-release tablet formulations,11 and as a carrier in dry powder inhalers. It is 
also used as a diluent in rapidly dispersing oral dosage forms. It is used in food 
applications as a bulking agent. 
 Therapeutically, mannitol administered parenterally is used as an osmotic diuretic, as 
a diagnostic agent for kidney function, as an adjunct in the treatment of acute renal 
failure. 
Stability and storage conditions 
Mannitol is stable in the dry state and in aqueous solutions.The bulk material should 
be stored in a well-closed container in acool, dry place. 
Incompatibilities 
 Mannitol solutions, 20% w/v or stronger, may be salted out by potassium chloride or 
sodium chloride. 
 Precipitation has been reported to occur when a 25% w/v mannitol solution was 
allowed to contact plastic. 
 Sodium cephapirin at 2 mg/mL and 30 mg/mL concentration is incompatible with 
20% w/v aqueous mannitol solution. 
 Mannitol is incompatible with xylitol infusion and may form complexes with some 
metals such as aluminum, copper, and iron.  
5.2.4. PVP K30 
Nonproprietary names 
BP: Povidone 
JP: Povidone 
PhEur: Povidone 
USP: Povidone 
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Synonyms 
E1201, Kollidon, Plasdone, poly[1-(2-oxo-1-pyrrolidinyl)ethylene], polyvidone, 
polyvinylpyrrolidone, povidonum, Povipharm, PVP, 1- vinyl-2-pyrrolidinone polymer. 
Chemical name 
1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical formula 
(C6H9NO)n 
Molecular weight 
2500–3000000 g/mol 
Structural formula 
 
 
 
 
 
Fig 4: Structure of PVP 
K30 
 
Table 3: uses of Povidone 
USE CONCENTRATION (%) 
Carrier for drugs 10-25 
Dispersing agent Upto 5 
Eye drops 2-10 
Suspending agent Upto 5 
Tablet binder, tablet diluent, or coating 
material 
0.5-5 
 
Description 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are 
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manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-value 
povidones are manufactured by drum drying and occur as plates. 
Applications in pharmaceutical formulation or technology 
 In tableting, povidone solutions are used as binders in wet-granulation processes. 
 Povidone is also added to powder blends in the dry form and granulated in situ by the 
addition of water, alcohol, or hydro alcoholic solutions. 
 Povidone is used as a solubilizer in oral and parenteral formulations, and has been 
shown to enhance dissolution of poorly soluble drugs from solid-dosage forms. 
 Povidone solutions may also be used as coating agents or as binders when coating 
active pharmaceutical ingredients on a support such as sugar beads. 
 Povidone is additionally used as a suspending, stabilizing, or viscosity-increasing 
agent in a number of topical and oral suspensions and solutions.  
 The solubility of a number of poorlysoluble active drugs may be increased by mixing 
with povidone.  
 Special grades of pyrogen-free povidone are available and have been used in 
parenteral formulations. 
Stability and storage conditions 
Povidone darkens to some extent on heating at 150˚C, with a reduction in aqueous 
solubility. It is stable to a short cycle of heat exposure around 110–130˚C, steam sterilization 
of an aqueous solution does not alter its properties. Aqueous solutions are susceptible to mold 
growth and consequently require the addition of suitable preservatives. Povidone may be 
stored under ordinary conditions without undergoing decomposition or degradation. 
However, since the powder is hygroscopic, it should be stored in an airtight container in a 
cool, dry place. 
Incompatibilities 
Povidone is compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other chemicals. It forms molecular adducts in solution with 
sulfathiazole, sodium salicylate, salicylic acid, phenobarbital, tannin, and other compounds. 
The efficacy of some preservatives, e.g. thimerosal, may be adversely affected by the 
formation of complexes with povidone. 
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5.2.5. HPMC K4M 
Nonproprietary names 
BP: Hypromellose 
JP: Hypromellose 
PhEur: Hypromellose 
USP: Hypromellose 
Synonyms 
Benecel MHPC, E464, hydroxypropyl methylcellulose, HPMC, hypromellosum, 
Methocel, methylcellulose propylene glycol ether, methyl hydroxypropylcellulose, Metolose, 
MHPC, Pharmacoat, Tylopur, Tylose MO. 
Chemical name 
Cellulose hydroxypropyl methyl ether 
Molecular weight 
10000–1500000 g/mol 
 Structural Formula 
 
 
 
 Fig 5: Structure of HPMC K4M 
Functional category 
Bioadhesive material, coating agent, controlled-release agent, dispersing agent, 
dissolution enhancer, emulsifying agent, emulsion stabilizer, extended-release agent, film-
forming agent, foaming agent, granulation aid, modified-release agent, mucoadhesive, 
release-modifying agent, solubilizing agent, stabilizing agent, suspending agent, sustained-
release agent, tablet binder, thickening agent, viscosity-increasing agent. 
 Description 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular 
powder 
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Applications in pharmaceutical formulation or technology 
 Hypromellose is widely used in oral, ophthalmic, nasal, and topical pharmaceutical 
formulations. 
 In oral products, hypromellose is primarily used as a tablet binder, in film-coating, 
and as a matrix for use in extended release tablet formulations. Concentrations 
between 2% and 5% w/w may be used as a binder in either wet- or dry-granulation 
processes.  
 High-viscosity grades may be used to retard the release of drugs from a matrix at 
levels of 10–80% w/w in tablets and capsules. 
 Hypromellose is also used in liquid oral dosage forms as a suspending and/or 
thickening agent at concentrations ranging from 0.25–5.0%. 
 Depending upon the viscosity grade, concentrations of 2–20% w/w are used for film-
forming solutions to film-coat tablets. 
 Lower viscosity grades are used in aqueous film-coating solutions, while higher-
viscosity grades are used with organic solvents. 
 Hypromellose is also used as a suspending and thickening agent in topical 
formulations 
 
Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, 
hypromellose will not complex with metallic salts or ionic organics to form insoluble 
precipitates. 
Stability and storage conditions 
Hypromellose powder is a stable material, although it is hygroscopic after drying. 
Solutions are stable at pH 3–11. Hypromellose undergoes a reversible sol–gel transformation 
upon heating and cooling, respectively. The gelation temperature is 50–90˚C, depending upon  
the grade and concentration of material. Hypromellose powder should be stored in a well-
closed container, in a cool, dry place. 
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5.2.6. Crospovidone 
Nonproprietary Names 
BP: Crospovidone 
PhEur: Crospovidone 
USP-NF: Crospovidone 
Synonyms 
Crospovidonum, Crospopharm, crosslinkedpovidone, E1202, Kollidon CL, Kollidon 
CL-M, Polyplasdone XL, PolyplasdoneXL-10, polyvinylpolypyrrolidone, PVPP, 1-vinyl-2-
pyrrolidinone homopolymer. 
Chemical Name 
1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical Formula 
 (C6H9NO)n 
Molecular Weight 
>1 000000 g/mol 
Structural Formula 
 
 
 
 
    
 
 
Fig 6: Structure of Crospovidone 
 Functional Category 
Tablet disintegrant 
Description 
Crospovidone is a white to creamy-white, finely divided, free flowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder. 
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 Applications in Pharmaceutical Formulation or Technology 
 Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at 2–
5% concentration in tablets prepared by direct compression or wet- and dry-
granulation methods.  
 Larger particles provide a faster disintegration than smaller particles. Crospovidone 
can also be used as a solubility enhancer. 
Stability and Storage Conditions 
Since crospovidone is hygroscopic, it should be stored in an airtight container in a 
cool, dry place. 
Incompatibilities 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular adducts 
with some materials 
5.2.7. Croscarmellose Sodium 
Nonproprietary Names 
BP: Croscarmellose Sodium 
JP: Croscarmellose Sodium 
PhEur: Croscarmellose Sodium 
USP-NF: Croscarmellose Sodium 
Synonyms 
Ac-Di-Sol, carmellosumnatricumconexum, crosslinkedcarboxymethylcellulose sodium, 
Explocel, modified cellulose gum, NymcelZSX, Pharmacel XL, Primellose, 
SolutabandVivasol. 
Chemical Name 
Cellulose, carboxymethyl ether, sodium salt, crosslinked 
 Structural Formula 
 
 
 
Fig 7: Structure of Croscarmellose Sodium 
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Functional Category 
Tablet and capsule disintegrant 
Description 
Croscarmellose sodium occurs as an odorless, white or grayish white powder. 
Applications in Pharmaceutical Formulation or Technology 
 Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant 
for capsules, tablets and granules. In tablet formulations, croscarmellose sodium may 
be used in both direct-compression and wet-granulation processes. 
 When used in wet granulations, the croscarmellose sodium should be added in both 
the wet and dry stages of the process (intra- and extra granularly) so that the wicking 
and swelling ability of the disintegrant is best utilized. 
 Croscarmellose sodium at concentrations up to 5% w/w may be used as a tablet 
disintegrant, although normally 2% w/w is used in tablets prepared by direct 
compression and 3% w/w in tablets prepared by a wet-granulation process. 
 
Table 4: Uses of croscarmellose sodium. 
Use Concentration (%) 
Disintegration in capsules 10-25 
Disintegration in tablets 0.5-5.0 
 
Stability and Storage Conditions 
Croscarmellose sodium is a stable though hygroscopic material. A model tablet 
formulation prepared by direct compression, with croscarmellose sodium as a disintegrant, 
showed no significant difference in drug dissolution after storage at 30˚C for 14 months. 
Croscarmellose sodium should be stored in a well-closed container in a cool, dry place. 
Incompatibilities 
The efficacy of disintegrants, such as croscarmellose sodium, may be slightly reduced 
in tablet formulations prepared by either the wet-granulation or direct-compression process 
that contain hygroscopic excipients such as sorbitol. Croscarmellose sodium is not 
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compatible with strong acids or with soluble salts of iron and some other metals such as 
aluminum, mercury, and zinc. 
 
5.2.8. Sodium Starch Glycolate 
Nonproprietary Names 
BP: Sodium Starch Glycolate 
PhEur: Sodium Starch Glycolate 
USP-NF: Sodium Starch Glycolate 
Synonyms 
Carboxymethyl starch, sodium salt, carboxymethylamylumnatricum, Explosol, 
Explotab, Glycolys, Primojel, starch carboxymethyl ether, sodium salt, Tablo, Vivastar P 
 Chemical Name 
Sodium carboxymethyl starch 
 Structure 
 
                      Fig 8: Structure of Sodium Starch Glycolate 
 Functional Category 
Tablet and capsule disintegrant 
Description 
Sodium starch glycolate is a white or almost white free-flowing very hygroscopic 
powder. The granules show considerable swelling in contact with water. 
Applications in Pharmaceutical Formulation or Technology 
 Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulations. It is commonly used in tablets prepared by either 
direct-compression or wet-granulation processes. 
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  The usual concentration employed in a formulation is between 2% and 8%, with the 
optimum concentration about 4%, although in many cases 2% is sufficient.  
 Disintegration occurs by rapid uptake of water followed by rapid and enormous 
swelling. 
 Although the effectiveness of many disintegrants is affected by the presence of 
hydrophobic excipients such as lubricants, the disintegrant efficiency of sodium starch 
glycolate is unimpaired. 
 Increasing the tablet compression pressure also appears to have no effect on 
disintegration time. 
 Sodium starch glycolate has also been investigated for use as a suspending vehicle. 
Stability and Storage Conditions 
Tablets prepared with sodium starch glycolate have good storage properties. Sodium 
starch glycolate is stable although very hygroscopic, and should be stored in a well-closed 
container in order to protect it from wide variations of humidity and temperature, which may 
cause caking. 
The physical properties of sodium starch glycolate remain unchanged for up to 3 
years if it is stored at moderate temperatures and humidity. 
Incompatibilities 
Sodium starch glycolate is incompatible with ascorbic acid. 
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6. MATERIALS 
6.1.1. List of equipment used 
Table 5: List of equipment and manufacturers 
INSTUMENT SUPPLIER 
Weighing balance Sartorius 
Electronic balance Essae DS-852 
Mechanical stirrer Vision labs 
Tray dryer Millennium equipment Pvt. Ltd(METD-6G)  
Tapped density apparatus Electro lab (ETD-1020) 
Compression machine Rimekkarnavathi 
Hardness testing apparatus Pharmag tester 
Friability test apparatus Electro lab friabilator 
Disintegration tester(USP) Electro lab(ED-2AL) 
Dissolution test system Electro lab 
Rapid mixer granulator Saral engineering(RMG5-15) 
HPLC RS spectra 
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6.1.2. List of materials used 
Table6: List of materials and their suppliers 
 
 
 
 
CHEMICAL SUPPLIER 
Tianeptine sodium RA chemPharma Ltd, Hyd, India  
Mannitol Roquette,  Pune, India 
Croscarmellose sodium FMC biopolymer, Mumbai, India  
PVP K-30 Anshul agencies, Mumbai, India 
HPMC K4M Colorcon, Pune, India 
Sodium starch glycolate(glycol YS) Signet chemicals, Hyd, India 
Magnesium stearate Ferro chemicals, Mumbai, India 
Talc Signet chemicals, Hyd, India 
Crospovidone(Polyplasdone XL-
10) 
Signet chemicals, Hyd, India 
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6.2. METHODOLOGY 
6.2.1. Preformulation Studies 
Preformulation involves the application of biopharmaceutical principles to the 
physicochemical parameters of drug substance are characterized with the goal of 
designing optimum drug delivery system45 
6.2.1.1. Angle of repose 
The angle of repose of API powder was determined by funnel method. The 
accurately weighed powder blend was taken in the funnel. The height of the funnel 
was adjusted in a way that, it measures 2.5 cm from the surface level. The powder 
blend is allowed to flow through the funnel freely on to the surface. The diameter of 
the powder cone is measured and angle of repose is calculated using the following 
equation.46 
tan θ = h/r 
Where, h and r are the height and radius of the powder cone. 
Table 7: Flow Properties and Corresponding Angle of Repose 
Flow property Angle of repose 
Excellent 25-30 
Good 31-35 
Fair aid not needed 36-40 
Passable- may hang up 41-45 
Poor must agitate, vibrate 46-55 
Very poor 56-65 
Very, very poor >66 
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6.2.1.2. Bulk density 
The powder sample was screened through sieve No.18 and the sample 
equivalent to 25 gm was weighed and filled in a 100 mL graduated cylinder and the 
powder was leveled and the unsettled volume, V0 was noted. The bulk density is 
calculated in g/cm3 by the formula. 
Bulk density = M/V0 
Where, M = Powder mass 
            V0 = apparent unstirred volume 
6.2.1.3. Tapped density 
The powder sample under test was screened through sieve No.18 and the 
weight of the sample equivalent to 25 gm was filled in a 100 mL graduated cylinder. 
The mechanical tapping of cylinder was carried out using tapped density tester at a 
nominal rate for 500 times initially and the tapped volume V0 was noted. The 
difference between two tapping volume was less than 2%, Vb is considered as a 
tapped volume Vf. The tapped density is calculated in g/cm3 by the formula. 
Tapped density=M/Vf 
Where, M =weight of sample power taken 
Vf = tapped volume 
6.2.1.4. Compressibility index 
The Compressibility Index of the powder blend was determined by Carr’s 
compressibility index to know the flow character of the powder. The formula for 
Carr’s Index is as below: 
Carr’s Index (%) = [(TD-BD) /TD] x100 
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6.2.1.5. Hausner’s ratio 
The ratio of tapped density to bulk density of the powder is called the 
Hausner’s ratio. It is calculated by the following equation. 
H = ρT / ρB 
Where, ρT = tapped density, ρB = bulk density 
Table 8: Scale of Flowability 
Compressibility index (%) Flow character Hausner’s ratio 
≤ 10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very, very poor >1.60 
 
6.2.2. Assay of Tianeptine Sodium by HPLC 
6.2.2.1. Preparation of mobile phase 
52 volumes of acetonitrile and 48 volumes of a 2 g/l solution of sodium lauryl 
sulphate were mixed and pH was adjusted to 2.5 using phosphoric acid. 
6.2.2.2. Preparation of diluent 
Degassed mixture of water and methanol were prepared in the ratio of 50:50 
and filtered 
6.2.2.3. Preparation of standard solution 
50 mg of Tianeptine sodium working standard was weighed and transferred 
into a 100 mL volumetric flask, to that 70 mL of diluents were added and sonicated to 
dissolve the content. Volume was made up to the mark with the diluent. 5 mL of 
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above solution was transferred into a 50 mL volumetric flask and vol made up to the 
mark with diluent. The prepared solution was filtered through 0.45 µ nylon membrane 
filter paper. 
6.2.2.4. Preparation of sample solution 
50 mg of Tianeptine sodium fine tablet powder was taken into a 100 mL 
volumetric flask and 70 mL of diluents were added, sonicated for 20 min with 
intermittent shaking and vol was made up to the mark with diluents. The prepared 
solution was passed through 0.45µ nylon filter paper. 5 mL of above solution was 
transferred into a 50 mL volumetric flask and made up to the mark with diluents. The 
solution was filtered through 0.45µ nylon filter paper. 
6.2.2.5. Chromatographic conditions 
Column: inertsil ODS-2,150 mm x 4.6 mm x 5 µm or its equivalent 
Flow rate: 1.0 mL/min 
Wave length: 220 nm 
Column temperature: 30˚C 
Injection volume: 10 µl 
Run time: 15 min 
6.2.2.6. Procedure 
10µl of diluents, six replicate injections of standard solution and two 
injections of sample solution were separately injected into the chromatograph, 
chromatograms were recorded and the peak responses were measured. 
Content was calculated using the formula 
    AT       Std. wt       5         100            50         P  
…… X   …………   X …..  X …………  X …….  X ……  X   AW = mg/tab 
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 AS        100           50       Sample wt   5          100 
AT = peak area of Tianeptine sodium in sample solution 
AS = average peak area of Tianeptine sodium in standard solution. 
Stdwt = weight of Tianeptine sodium standard 
Sample wt. = weight of the sample. 
P = potency 
AW = average weight of the tablets 
6.2.3. Compatibility studies 
Compatibility studies were conducted to investigate and predict physico 
chemical interaction between drug substance and excipients and therefore to select 
suitability of chemically compatible excipients. Preformulation studies are carried out 
with the objective of ascertaining the incompatibility of the excipients used in the 
existing formulation and to avoid any excipient, which is incompatible with the drug 
in the final formulation. 
Table9: Composition of blends for compatibility study 
Batch no. Composition 
TIB001 Tianeptine sodium+ Mannitol+ HPMC+ 
Povidone+ CCS+ Talc+ Mg stearate 
TIB002 Tianeptine sodium+ Mannitol+ HPMC+ 
Povidone+ CP+ Talc+ Mg stearate 
TIB003 Tianeptine sodium+ Mannitol+ HPMC+ 
Povidone+ SSG+ Talc+ Mg stearate 
3.2.4. Manufacturing procedure 
All the ingredients were weighed as per the manufacturing formula, sifted 
through #50 and collected separately. 
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6.2.4.1. Dry mixing 
Intragranular materials were mixed for 3 minutes in a polybag. 
6.2.4.2. Granulation 
To this blend binder solution was added slowly within 3 minutes. 
6.2.4.3. Drying and sizing 
After complete addition of binder solution, mixing was continued for another 
two minutes to break the lumps. This wet mass was transferred into tray drier and 
dried at 45˚C. After semi drying this material was passed through mesh no #12 and 
drying was continued upto 2 hours. The granules were passed through mesh no #18.  
6.2.4.4. Prelubrication 
Super disintegrants were passed through mesh no # 40 and added to the above 
granules in a sandwich manner and blended for 3 min using polybag. 
6.2.4.5. Lubrication 
To this blend magnesium stearate and talc (passed through mesh no #60) were 
added and blended for 2 minutes. 
6.2.4.6. Tablet compression 
Tablets were compressed using compression machine with lubricated blend, 
employing appropriate punch toolings. 
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Fig. 9: Flow chart for the manufacturing process 
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Table10: Formulae of Tianeptine sodium IR tablets prepared 
Ingredients 
(mg) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Tianeptine 
sodium 
12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
Mannitol 133.
7 
130.
3 
128.
6 
133.
7 
130.
3 
128.
6 
133.
7 
130.
3 
128.
6 
Polyplasdone 
XL 
2.55 4.25 8.5 - - - - - - 
Croscarmellos
e sodium 
- - - 2.55 4.25 8.5 - - - 
Sodium starch 
glycolate 
- - - - - - 2.55 4.25 8.5 
Povidone 5.1 5.1 5.1 5.1 5.1 5.1 5.1 5.1 5.1 
Purified water QS QS QS QS QS QS QS QS QS 
Hypromellose 8.5 8.5 8.5 8.5 8.5 8.5 8.5 8.5 8.5 
Polyplasdone 
XL 
2.55 4.25 1.7 - - - - - - 
Croscarmellos
e sodium 
- - - 2.55 4.25 1.7 - - - 
Sodium starch 
glycolate 
- - - - - - 2.55 4.25 1.7 
Magnesium 
stearate 
1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 
talc 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 
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6.2.5. Evaluation Parameters 
6.2.5.1. Thickness 
The thickness of the tablets was determined by using Digital micrometer. Ten 
individual tablets from each batch were used and the results averaged. 
6.2.5.2. Weight variation 
Twenty tablets were randomly selected from each batch and individually 
weighed .The average weight and standard deviation were calculated. The test for 
weight variation is passed only if not more than two of the individual tablet weights 
deviate from the average weight by more than the allowed percentage deviation and 
none deviate by more than twice the percentage shown. 
6.2.5.3. Friability 
The friability values of the tablets were determined using a Roche-type 
friabilator. Accurately weighed six tablets were placed in Roche friabilator and 
rotated at 25 rpm for 4 min. Percentage friability was calculated using the following 
equation. 
                                      Initial wt – final wt 
                              % = --------------------------- x 100 
                                             Initial wt 
6.2.5.4. Disintegration test 
Six tablets were taken randomly from each batch and placed in USP 
disintegration apparatus baskets, which is repeatedly immersed 30 times per minute 
into a thermostatically controlled fluid at 37ºc and observed over the time described in 
the individual monograph. To fully satisfy the test the tablets disintegrate completely 
into a soft mass having no palpably firm core. 
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6.2.5.5. Dissolution 
The dissolution studies of the prepared tablets were carried using Electro lab 
apparatus II. Dissolution was performed in 900 mL of water, 6.8 pH buffer, pH 4.5 
acetate buffer and in CDER recommended media i.e. 0.1 N Hcl at 37 ±0.5˚C at 100 
rpm. An auto sampler, coupled to the dissolution apparatus was programmed to 
withdraw and replace 10 mL of the dissolution media at 15, 30, 45, 60 and 90 min. 
Preparation of standard solution 
35 mg of tianeptine sodium working standard was weighed and transferred to 
100 mL volumetric flask. 50 mL of methanol was added and sonicated to dissolve the 
content.1 mL of the above solution was taken and 50 mL of media was added. The 
above solution was filtered through 0.45 µ nylon membrane filter paper. 
Procedure 
10 µl of diluents, five replicate injections of standard solution and two 
injections of sample solution were injected into the chromatograph and the peak areas 
were measured from the chromatograms.  
Chromatographic conditions 
Column: inertsil ODS-2,150 mm x 4.6 mm x 5 µm or its equivalent 
Flow rate: 1.0 mL/min 
Wave length: 220 nm 
Column temperature: 30˚C 
Injection volume: 50 µl 
% labeled amount of tianeptine sodium dissolved 
   AT          WS      5          900        P        100  
= …… X   ……   X …..  X …….  X …….  X …………………… 
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   AS        100        100                 100       label claim in mg 
AT = peak area of Tianeptine sodium in sample solution 
AS = average peak area of Tianeptine sodium in standard solution. 
Ws = Weight of tianeptine sodium working standard taken in mg. 
P = potency. 
3.2.5.6. Stability Studies 
The selected batch was kept at 40°C with 75% RH and the samples were 
withdrawn at 30, 60 and 90 days for physical and in vitro evaluation of drug release. 
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7.RESULTS AND DISCUSSION 
7.1. PREFORMULATION STUDIES 
7.1.1. Drug-Excipient compatibility study 
Table11: Results on drug – excipient compatibilities studies – TIB001 
S
 
N 
Test 
cond
ition
s 
Day 
0 
Day 15 Day 30 
25°C/60
%RH 
30°C/75
%RH 
40°C/75
%RH 
25°C/60
%RH 
30°C/75
%RH 
40°C/75
%RH 
1 PA WC
C 
WCC WCC WCC WCC WCC WCC 
2 Assa
y (%) 
100 103.7 102.2 104.4 102.8 103.5 104.3 
WCC= White colored crystalline powder; PA= Physical appearance 
Table 12: Results on drug – excipient compatibilities studies – TIB002 
 
WCC= White colored crystalline powder; PA= Physical appearance 
 
 
S
 
N 
Test 
condi
tions 
Day 
0 
Day 15 Day 30 
25°C/60
%RH 
30°C/75
%RH 
40°C/75
%RH 
25°C/60
%RH 
30°C/75
%RH 
40°C/75
%RH 
1 PH WCC WCC WCC WCC WCC WCC WCC 
2 Assa
y (%) 
102 103.0 104.8 104.8.0 103.0 104.9 105.7 
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Table 13: Results on drug – excipient compatibilities studies – TIB003 
S
N 
Test 
condit
ions 
Da
y 0 
Day 15 Day 30 
25°C/60
%RH 
30°C/75
%RH 
40°C/75
%RH 
25°C/60
%RH 
30°C/75
%RH 
40°C/75
%RH 
1 PA W
CC 
WCC WCC WCC WCC WCC WCC 
2 Assay 
(%) 
10
5.3 
103.8 100.6 103.6 105.1 105.5 106.1 
 
WCC= White colored crystalline powder; PA= Physical appearance 
 
Fig. 10: XRD of Tianeptine sodium (API) 
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Fig. 11: DSC of Tianeptine (API) 
 
Fig. 12: XRD of TIB001 (day 0) 
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Fig.13: DSC of TIB001 
Fig.14: XRD of TIB002 
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Fig.15: DSC of TIB002 
Fig.16: XRD of TIB003 
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Fig.17: DSC of TIB003 
Fig.18: XRD of Placebo 
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Fig. 19: DSC of placebo 
The preformulation studies indicated that the assay of the blends were 
consistent, at all conditions, indicating that the drug was stable in the blend for the 
duration of the study. 
Further the XRD of API showed that the API is predominantly crystalline, and 
the corresponding DSC showed endothermic transition around 170˚C. However, the 
delta H values were around 12 to 16. The low J/g value is indicative of the fact that 
the drug is predominantly crystalline. 
The DSC of the blend and that of Stablon showed a sharp endothermic 
transition around 169˚C, which could be attributed to mannitol, as the melting point of 
mannitol is between 165 to 170 ˚C. 
The DSC and XRD studies were also suggestive of lack of any interaction 
(solid state) of drug with the selected excipients. 
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Table14: Preparation of standard graph of tianeptine sodium 
LEVEL (%) CONCENTRATION PEAK AREA 
20 0.0028 395032 
50 0.007 987580 
80 0.0112 1580129 
100 0.014 1875161 
120 0.0168 2370193 
 
 
 
 
 
 
 
 
 
Fig.20: Calibration curve of Tianeptine sodium 
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Table15: Powder characteristics of the formulations F1-F5 
 
Evaluation 
parameters 
F1 F2 F3 F4 F5 
Bulk density 
(g/cc) 
0.445±0.01 0.460±0.02 0.466±0.02 0.488±0.05 0.503±0.09 
Tapped density 
(g/cc) 
0.521±0.05 0.523±0.03 0.532±0.04 0.568±0.04 0.586±0.11 
Hausner’s ratio 1.07±0.11 1.13±0.09 1.15±0.09 1.16±0.08 1.16±0.08 
Angle of repose 34.9±2.30 34.54±2.07 33.39±3.20 34.05±3.25 33.17±2.60 
Carr’s index (%) 18.0±4.90 17.2±3.00 17.4±4.00 17.2±3.80 15.1±5.80 
All the values are expressed as mean ± S.D; No. of trails (n)=6 
 
 
Table16: Powder characteristics of the formulations F6-F9 
 
Evaluation parameters F6 F7 F8 F9 
Bulk density (g/cc) 0.512±0.11 0.462±0.07 0.508±0.10 0.486±0.10 
Tapped density (g/cc) 0.574±0.12 0.545±0.08 0.584±0.13 0.563±0.10 
Hausner’s ratio 1.12±0.08 1.18±0.10 1.14±0.07 1.16±0.09 
Angle of repose 34.74±3.30 33.78±2.50 36.18±2.20 35.14±3.00 
Carr’s index (%) 16.7±4.30 19.4±3.00 14.6±4.50 17.2±4.10 
All the values are expressed as mean ± S.D; No. of trails (n)=6 
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Table17: Evaluation of post compression parameters of F1-F5 
Test 
Stablo
n 
F1 F2 F3 F4 F5 
Weight 
variation 
(mg) 
169 
169.2±2.3
0 
169.9±2.5
0 
170.2±1.7
0 
169.9±2.1
0 
170.5±1.9
0 
Thickness 
(mm) 
3.5 3.63±0.09 3.89±0.07 3.68±0.15 3.87±0.05 3.89±0.02 
Hardness 
(kg/cm2) 
7.2 7.1±0.76 6.2±0.20 7.1±0.80 6.7±0.80 7.1±0.80 
Friability 
(%) 
0.12 0.12±0.90 0.12±0.67 0.15±0.84 0.14±0.79 0.12±0.52 
Disintegratio
n time(min) 
3.30 
3.15 
±3.80 
3.10±4.10 3.00±2.30 
3.60 
±3.60 
2.55±2.10 
Content 
uniformity 
(%) 
101.0 100.5 100.1 100.0 99.3 99.8 
All the values are expressed as mean ± S.D; No. of trails (n) =6 
Table18: Evaluation of post compression parameters of F6-F9 
Test Stablon F6 F7 F8 F9 
Weight variation (mg) 169 169.9±2.2 170.3±2.1 170.2±2.0 169.7±1.8 
Thickness(mm) 3.5 3.78±0.01 3.79±0.03 3.67±0.03 3.76±0.03 
Hardness(kg/cm2) 7.2 7.2±0.8 7.5±0.3 6.9±0.3 6.5±0.2 
Friability (%) 0.12 0.14 0.15 0.14 0.12 
Disintegration time(min) 3.30 2.10±2.4 3.30±3.4 3.17±2.5 3.10±3.0 
Content uniformity (%) 101.0 101.0 99.5 100.5 100.0 
All the values are expressed as mean ± S.D; No. of trails (n)=6
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Table19: Dissolution profiles of tianeptine IR tablets in 0.1 N Hcl 
Time 
(min) 
Percentage of tianeptine dissolved 
Stablon F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 0 
5 62.1 53.0±0.9 67.8±0.87 57.1±1.3 59.0±1.4 65.5±1.5 77.0±1.3 50.0±0.9 51.3±2.0 53.2±1.6 
10 84.3 66.7±1.4 79.4±1.5 85.9±1.1 68.0±0.6 72.7±0.5 87.7±1.5 87.6±1.2 87.9±1.7 89.1±0.7 
15 88.1 75.6±1.3 88.5±1.8 88.9±1.5 77.4±0.9 84.0±0.7 91.0±1.1 98.8±0.98 97.9±0.83 99.0±1.32 
30 95.9 89.6±1.43 94.4±1.4 94.6±0.87 84.5±1.43 90.1±1.53 95.4±0.68 99.4±0.71 98.0±1.43 99.3±0.91 
45 99.0 95.5±1.43 94.9±1.75 97.1±2.0 90.4±0.93 92.5±0.75 97.8±1.34 102.1±1.37 100.9±0.67 102.7±0.85 
60 100.4 98.5±1.32 98.9±1.76 96.8±0.87 97.4±0.99 98.1±1.41 98.8±1.8 105.8±1.21 102±0.86 97.8±1.11 
f1 - 9.6 3.4 2.6 10.0 6.3 4.6 7.1 5.6 6.4 
f2 - 49.82 71 76.5 49.87 59.5 59.4 56.5 59.8 59.1 
All the values are expressed as mean ± S.D; No. of trails (n)=6 
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Table20: Dissolution profiles of tianeptine IR tablets in pH 4.5 acetate buffer 
Time 
(min) 
Percentage of tianeptine dissolved 
Stablon F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 0 
5 93 70.6±1.21 90.8±1.54 83.2±1.87 75.6±0.98 81.1±0.65 87.4±1.54 58.4±1.74 64.7±1.47 71.4±0.68 
10 92.2 85.4±0.98 100±1.35 94.4±1.74 82.1±1.95 84.2±1.78 89.8±0.93 81.1±1.57 85.4±1.34 87.6±0.65 
15 92.4 91.5±1.43 102.2±1.68 98.3±1.48 84.5±0.69 86.5±1.57 91.4±1.54 91.1±0.96 92.4±0.67 91.9±1.56 
30 92.5 97.5±1.22 103.9±1.76 99.1±1.97 92.9±0.85 94.7±1.43 95.1±1.59 94.1±0.69 95.6±0.43 97.8±1.75 
45 93.9 98±1.54 105±1.83 99.0±0.97 97.6±0.69 95.4±0.58 96.0±1.82 100.1±1.48 102.1±2.0 104.5±1.798 
60 94 99.0±1.4 105±1.53 100.8±0.83 98.0±0.71 97.1±0.63 96.1±1.76 101.5±1.48 99.8±1.68 104.1±0.91 
f1 - 8.3 9.7 6.5 8.2 6.19 3 11.7 11.7 9.9 
f2 - 49.8 51.4 59.8 51.9 58.9 75.4 40.7 45.1 48.0 
All the values are expressed as mean ± S.D; No. of trails (n)=6 
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Table21: Dissolution profiles of tianeptine IR tablets in pH 6.8 phosphate buffer 
Time 
(min) 
Percentage of tianeptine dissolved 
Stablon F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 0 
5 75.4 75.2±1.98 86.2±1.53 75.2±1.78 76.7±0.86 82.1±0.59 86.7±0.18 69.1±1.59 71.1±1.63 75.4±1.53 
10 87 85±0.63 101.5±1.54 93.3±1.83 86.1±0.99 88.4±0.32 90.3±1.43 81.1±1.67 81.5±1.37 87.1±1.87 
15 91.6 89.8±0.92 103.2±0.72 97.1±0.69 88.4±1.76 91.8±0.92 93.8±0.72 86.7±1.84 89.1±1.31 88.4±1.66 
30 98.3 94.9±1.31 102.7±0.72 98.7±1.41 92.0±0.86 96±0.65 98±0.72 92.9±1.49 95.1±1.52 94.8±0.92 
45 99 96.3±1.46 103.2±1.75 98.7±0.93 97.1±0.74 98.9±0.49 98.8±1.64 100.9±1.65 102.7±0.87 103.1±0.69 
60 99 95.7±1.43 103.2±0.48 97.3±0.38 97.0±1.75 99.0±0.73 98.4±1.87 100.1±1.71 103.4±0.39 102.7±0.63 
f1 - 2.5 9.3 2.7 2.9 2.0 3.3 4.8 3.7 2.75 
f2 - 78.6 51.5 72 74 75.3 65 65.9 71.1 75.2 
All the values are expressed as mean ± S.D; No. of trails (n)=6 
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Table22: Dissolution profiles of tianeptine IR tablets in water 
Time(min) Percentage of tianeptine dissolved 
Stablon F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 0 
5 72 56.7±1.63 81.3±1.54 80.8±1.32 68.2±1.43 74.4±1.76 76.8±0.74 54.1±0.74 69.1±0.81 72.5±1.15 
10 88.6 80.8±1.31 93±1.56 95.5±1.48 79.4±0.46 81.4±1.67 82.8±0.28 67.1±0.71 77.9±1.43 
15 93 87.1±0.43 95.9±0.63 97.7±1.74 80.8±1.65 82.9±1.49 84.1±1.46 79.1±1.82 85.6±1.54 81.1±1.36 
30 94 93.6±0.97 92.8±1.76 98.5±1.67 81.1±1.45 84.1±1.41 87.4±1.81 89.1±2.0 91.5±0.72 89.5±0.54 
45 95 96.4±1.13 100.3±1.42 99±1.43 80±0.43 82.5±0.47 86.4±1.98 94.5±1.32 94.5±1.56 94.8±1.75 
60 95.6 98.4±1.65 99.8±1.69 100.1±1.12 81.4±1.82 81.2±1.03 87.7±0.34 99.1±0.72 99.8±1.19 100.8±1.06 
f1 - 6.3 5.1 6.3 12.7 10 8 11.7 5.3 6.2 
f2 - 55.9 63.8 61.4 46.2 49.5 56.7 88.5 61.5 56.9 
All the values are expressed as mean ± S.D; No. of trails (n)=6 
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Fig.21: Dissolution profiles of Stablon and tianeptine IR tablets in 0.1 N Hcl 
 
 
Fig.22: Dissolution profiles of tianeptine IR tablets at 3% concentration of 
different super disintegrants 
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Fig.23: Dissolution profiles of tianeptine IR tablets at 5% concentration of 
different super disintegrants 
 
Fig.24: Dissolution profiles of tianeptine IR tablets at 6% concentration of 
different super disintegrants 
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Fig.25: Dissolution profiles of tianeptine IR tablets at different concentrations of 
crospovidone 
 
Fig.26: Dissolution profiles of tianeptine IR tablets at different concentrations of 
croscarmellose sodium 
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Fig.27: Dissolution profiles of tianeptine IR tablets at different concentrations of 
sodium starch glycolate 
 
Fig.28: Dissolution profiles of Stablon and tianeptine IR tablets in acetate buffer 
pH 4.5 
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Fig.29: Dissolution profiles of Stablon and tianeptine IR tablets in phosphate 
buffer pH 6.8 
 
Fig.30: Dissolution profiles of Stablon and tianeptine IR tablets in water 
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Table23: Dissolution parameters of Tianeptine sodium IR tablets prepared (F1-
F4) 
Parameters 
Formulations 
Stab F1 F2 F3 F4 
 
T50% (min) 
 
M1 4.00 5.00 2.75 4.25 3.75 
M2 2.00 3.50 1.75 3.00 3.50 
M3 3.50 3.25 3.00 3.00 3.00 
M4 3.00 4.50 2.00 2.75 4.00 
 
T80(min) 
M1 9.00 19.50 10.50 9.00 20.00 
M2 4.00 13.25 4.00 4.50 8.25 
 
M3 7.00 7.75 4.75 6.50 6.75 
M4 6.75 9.75 4.75 4.75 14.00 
 
DE30 (%) 
M1 77.74 67.55 77.75 77.1 68.09 
M2 84.82 80.87 91.84 87.14 77.67 
M3 82.17 80.35 91.35 85.12 79.60 
M4 81.26 75.35 86.69 86.57 71.80 
 
PD10 
M1 84.30 66.70 79.40 85.90 68.00 
M2 93.00 85.40 100.0 94.40 82.10 
M3 87.00 85.00 101.50 93.30 86.10 
M4 88.60 80.80 93.00 95.50 79.40 
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Table24: Dissolution parameters of Tianeptine sodium IR tablets prepared (F5-
F9) 
Note: 
M1-0.1 N Hcl 
M2-Acetate buffer pH 4.5 
M3-Phosphate buffer pH 6.8 
M4-Purified water 
Parameters 
Formulation 
Stab F5 F6 F7 F8 F9 
 
T50% (min) 
 
M1 4.00 3.00 3.00 5.00 4.00 5.00 
M2 2.00 3.25 3.00 4.50 3.50 3.50 
M3 3.50 3.25 3.00 3.75 3.75 3.50 
M4 3.00 1.75 2.00 4.50 3.50 3.00 
 
T80(min) 
M1 9.00 13.50 6.50 8.50 8.75 8.50 
M2 4.00 4.75 4.50 9.75 8.50 7.25 
 
 
M3 7.00 5.00 4.50 9.50 9.25 7.00 
M4 6.75 9.25 7.75 11.25 11.5 12.5 
 
DE30 (%) 
M1 77.74 73.55 81.63 80.71 80.33 81.54 
M2 84.82 80.05 83.77 77.14 79.71 81.58 
M3 82.17 83.01 85.26 77.15 78.9 80.25 
M4 81.26 74.62 76.48 68.84 75.9 74.42 
 
PD10 
M1 84.30 72.70 87.70 87.60 87.90 89.10 
M2 93.00 84.20 89.80 81.10 85.40 87.60 
M3 87.00 88.40 90.30 81.10 81.50 87.10 
M4 88.60 81.40 82.80 67.10 77.90 77.60 
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Table 25: Dissolution of optimized formulation maintained for stability with 0.1 
N Hcl 
Time 
(min) 
% Drug release  in at 40°C/75 RH 
Initial 1st month 2nd month 3rd month 
0 0 0 0 0 
5 77.0 77.4 77.2 77.1 
10 87.7 87.6 87.4 87.3 
15 91.0 89.9 89.7 89.6 
30 95.4 95.2 95.1 94.9 
45 97.8 97.6 97.5 97.3 
60 98.8 98.7 98.6 98.4 
 
 
 
Table 26:  Dissolution of optimized formulation maintained for stability with pH 
4.5 Acetate buffer 
Time(min) 
% Drug release  in at 40°C/75 RH 
Initial 1st month 2nd month 3rd month 
0 0 0 0 0 
5 87.4 87.3 87.2 87.1 
10 89.8 89.6 89.4 89.3 
15 91.4 91.3 91.2 91.1 
30 95.1 95.0 94.8 94.7 
45 96.0 95.9 95.8 95.6 
60 96.1 96.0 95.9 95.8 
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Table 27:  Dissolution of optimized formulation maintained for stability with pH 
6.8 Phosphate buffer 
Time(min) % Drug release  in at 40°C/75 RH 
Initial 1st month 2nd month 3rd month 
0 0 0 0 0 
5 86.7 86.5 86.4 86.3 
10 90.3 90.2 90.1 89.9 
15 93.8 93.7 93.6 93.5 
30 98.8 98.7 98.6 98.5 
45 98.0 97.9 97.8 97.7 
60 98.4 98.4 98.3 98.2 
 
Table 28:  Dissolution of optimized formulation maintained for stability with 
water 
Time(min) 
% Drug release  in at 40°C/75 RH 
Initial 1st month 2nd month 3rd month 
0 0 0 0 0 
5 76.8 76.6 76.5 76.4 
10 82.8 82.6 82.4 82.3 
15 84.1 83.9 83.7 83.6 
30 87.4 87.3 87.2 87.1 
45 86.4 86.3 86.2 86.1 
60 87.7 87.5 87.4 87.3 
 results and Discussions 
 
 
Department of Pharmaceutics    78     J.K.K.Nattraja College of Pharmacy 
 
 
 
 
Fig.31:Comparative dissolution data of stability samples in 0.1 N Hcl 
 
 
Fig.32:Comparative dissolution data of stability samples in Acetate buffer pH 4.5 
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Fig.33: Comparative dissolution data of stability samples in Phosphate buffer pH 
6.8 
 
Fig.34:Comparative dissolution data of stability samples in water 
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No incompatibilities between tianeptine sodium, mannitol, povidone, 
hypromellose, super disintegrants (CP, SSG, and CCS), magnesium stearate and talc 
had been observed. Immediate release tablets containing 170 mg of tianeptine were 
prepared by using different proportions (3%, 5%, 6%) of croscarmellose sodium, 
crospovidone, sodium starch glycolate by wet granulation method. Hardness of the 
tablets was in the range of 6.0-7.5. Weight loss in the friability test was less than 0.2% 
in all the cases. All the IR tablets prepared contained tianeptine within 100±2.5% of 
the labeled claim. All the tablets disintegrated rapidly in the USP disintegration test.  
The disintegration time was dependent on the type of disintegrant used and as the 
disintegration is rapid they are considered suitable for immediate release. 
Polyplasdones are densely cross-linked homopolymers of N-vinyl 2-pyrrolidones. 
Their porous particle morphology enables them to rapidly absorb liquids into the 
tablet by capillary action and to generate rapid volume expansion and hydrostatic 
pressures that result in tablet disintegration. Visually, tablets formulated with 
Polyplasdones could be seen to rapidly disintegrate into more or less uniform fine 
particles, while tablets formulated with croscarmellose sodium and sodium starch 
glycolate appear to disintegrate much more slowly into more or less uniform coarse 
particles.  
Tablets containing croscarmellose sodium and sodium starch glycolate seemed 
to swell immediately. This was in accordance with earlier findings where tablets 
prepared with croscarmellose sodium and sodium starch glycolate showed 
tremendous swelling before disintegration (Gorman et al.1982, Wan & Prasad 1989, 
Yen et al. 1997). Further the rapid swelling of these tablets upon wetting may partly 
be attributed to the recovery of deformation. As per the results it is evident that tablets 
containing CP as disintegrant at a concentration of 6% disintegrated more rapidly 
followed by tablets containing CCS and SSG. 
In vitro dissolution studies 
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 Generally, the recommended dissolution media for in vitro dissolution testing 
can be used to guide formulation development and it is typically non discriminatory 
between formulation ingredients. Usually, drug release from immediate release tablets 
as used in the study, is driven more by the medium than the formulation ingredients. 
Discriminatory dissolution profiles are highly desirable for distinguishing between 
products having differences in pharmaceutical attributes (formulation or 
manufacturing process differences) as in the case in the present study, where in the 
difference in the formulation was with respect to disintegrant used and their 
concentrations. 
 Tianeptine dissolution profiles of the IR tablets in the recommended medium 
and discriminating mediums are given in table 5.9, 5.10, 5.11, 5.12 and shown in figs 
5.12-5.21. Dissolution parameters of the tablets are summarized in table 5.13, 5.14. 
Results have show that the tablets prepared with CP showed faster dissolution than 
the corresponding tablets prepared with CCS or SSG, in both the four media as also 
was evidenced by the t50% and t80% values. It is evident from the results that as the 
concentration of super disintegrant increased, dissolution rate was also increased. All 
the tablets except F2 and F4 exhibited not less than 85% dissolution in 0.1 n Hcl 
indicating that bioavailability of these tablets is not limited by dissolution. 
 Tablets prepared by 6% CCS exhibited lesser t50% and t80% values in all the 
media indicating that F6 is superior to remaining formulations. F6 exhibited highest 
DE30 and PD10 values in 0.1 N Hcl, where as in other media’s F2 exhibited higher 
values indicating that CP at 5% concentration is also effective for preparation of 
Tianeptine IR tablets. At all the concentrations CCS achieved faster dissolution 
compared to other super disintegrants at the same concentration and CP exhibited 
overlapping results with CCS and innovator Stablon.  
CP exhibited faster dissolution at 5% concentration, CCS at 6% concentration 
and SSG exhibited similar dissolution rates at all concentrations. The results clearly 
demonstrate the superiority of CCS to enhance the release of the drug even in the 
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discriminatory medium, and shows that the choice of the super disintegrant and its 
concentration has a significant impact on drug dissolution. A similar trend was 
observed for the tablets and the difference was not very apparent between the tablets 
containing CCS and CP as disintegrants. All the formulations except the F4 exhibited 
greater than 85% dissolution at 30 min in all the media indicating that they can be 
considered as waivers of in vivo relative bioavailability study and from f1, f2 values it 
is obvious that formulation F1-F6 exhibited similar dissolution profiles with that of 
innovator under the dissolution test conditions defined for rapidly dissolving products, 
they can be considered as waivers of in vivo bio equivalence according to FDA draft 
guidance. 
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8. SUMMARY 
The main objective of the study is to develop tianeptine IR tablets using 
various super disintegrants in different concentrations to achieve faster dissolution to 
match the innovator product Stablon-170 mg. Tablets were prepared by incorporating 
the super disintegrants at 3, 5, 6 % w/w. Tablet blends were prepared and 
micromeritic studies were carried out for those blends. Pure and formulated products 
of tianeptine were evaluated by HPLC at a wave length of 220 nm using inertsil ODS 
column. From the results obtained by HPLC, the calibration curve was constructed 
having regression value of 0.997. Assay values of the formulations were observed in 
the range of 99.3 to 101%. Compatibility studies were performed and it was observed 
that all the super disintegrants used were compatible with the drug. Dissolution 
studies were performed and it was found that formulation F6 have shown best results 
and comparable with the innovator (Stablon).   
 CONCLUSION  
From the above experimental results it can be concluded that: 
Immediate release tablets of tianeptine sodium can be prepared by using CCS, CP and 
SSG at different concentrations. 
 Immediate release tablets showed release depending on the concentration of 
the super disintegrant and also on the type of mechanism of disintegration of the super 
disintegrants CCS, SSG and CP. 
Tablet dimensions, weight and breaking force have no significant difference between 
tablets with different disintegrants. 
 The DSC, XRD spectra’s revealed that, there was no interaction between the 
drug and the disintegrants. From the study it is evident that a promising immediate 
release tablet formulation can be developed. Further in vivo investigation is required 
to establish efficacy of this formulations. 
 The study indicated that the dissolution rate increased with an increase in the 
super disintegrant concentration and significant results were observed with CCS even 
in discriminating media’s and apparent difference in dissolution rate was not observed 
between tablets formulated with CP and SSG. 
  Summary and Conclusion 
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 The study also indicated that all the formulations except F4 are bio waivers for 
in vivo relative bio availability study and formulations F1-F6 can be considered as 
waivers of in vivo bio equivalence study according to FDA guidelines.  
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